{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:08:52Z","timestamp":1793844532144,"version":"4.6.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T15:38:30Z","timestamp":1654789110000},"page":"5275-5293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Brighton Collaboration standardized template with key considerations for a benefit\/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273)"],"prefix":"10.1016","volume":"40","author":[{"given":"Brett","family":"Leav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Leav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tashawnee","family":"Gaines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Maggiacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denny","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gurwith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3-4","key":"10.1016\/j.vaccine.2022.06.005_b0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(02)00449-8","article-title":"The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)","volume":"21","author":"Bonhoeffer","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.005_b0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.005_b0015","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2022.06.005_b0020","doi-asserted-by":"crossref","unstructured":"Rein Verbeke, Ine Lentacker, Stefaan C. De Smedt, Heleen Dewitte, Three decades of messenger RNA vaccine development, Nano Today 2019; 28: 100766, ISSN 1748-0132, https:\/\/doi.org\/10.1016\/j.nantod.2019.100766.","DOI":"10.1016\/j.nantod.2019.100766"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.005_b0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2022.06.005_b0030","doi-asserted-by":"crossref","unstructured":"Karik\u00f3 K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23(2): 165\u201375. doi: 10.1016\/j.immuni.2005.06.008. PMID: 16111635.","DOI":"10.1016\/j.immuni.2005.06.008"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.005_b0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/nar\/27.1.196","article-title":"The RNA Modification Database: 1999 update","volume":"27","author":"Rozenski","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2022.06.005_b0040","doi-asserted-by":"crossref","unstructured":"Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012; 12(7): 479\u201391. doi: 10.1038\/nri3247. PMID: 22728526.","DOI":"10.1038\/nri3247"},{"key":"10.1016\/j.vaccine.2022.06.005_b0045","doi-asserted-by":"crossref","unstructured":"Fechter P, Brownlee GG. Recognition of mRNA cap structures by viral and cellular proteins. J Gen Virol. 2005 May;86(Pt 5):1239-1249. doi: 10.1099\/vir.0.80755-0. PMID: 15831934.","DOI":"10.1099\/vir.0.80755-0"},{"key":"10.1016\/j.vaccine.2022.06.005_b0050","doi-asserted-by":"crossref","unstructured":"Kozak M. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem. 1991 Oct 25;266(30):19867-70. PMID: 1939050.","DOI":"10.1016\/S0021-9258(18)54860-2"},{"key":"10.1016\/j.vaccine.2022.06.005_b0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther Deliv"},{"key":"10.1016\/j.vaccine.2022.06.005_b0060","doi-asserted-by":"crossref","first-page":"101142","DOI":"10.1016\/j.nantod.2021.101142","article-title":"Role of nanotechnology behind the success of mRNA vaccines for COVID-19","volume":"38","author":"Khurana","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.vaccine.2022.06.005_b0065","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2022.06.005_b0070","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2022.06.005_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.589959","article-title":"Advances in lipid nanoparticles for mRNA-based cancer immunotherapy","volume":"8","author":"Guevara","year":"2020","journal-title":"Front Chem"},{"key":"10.1016\/j.vaccine.2022.06.005_b0080","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/acs.molpharmaceut.0c00992","article-title":"Enhanced delivery of siRNA to retinal ganglion cells by intravitreal lipid nanoparticles of positive charge","volume":"18","author":"Huang","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.vaccine.2022.06.005_b0085","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1039\/D0BM01609H","article-title":"Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomater Sci"},{"key":"10.1016\/j.vaccine.2022.06.005_b0090","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41563-020-00886-0","article-title":"Membrane-destabilizing ionizable phospholipids for organselective mRNA delivery and CRISPR-Cas gene editing","volume":"20","author":"Liu","year":"2021","journal-title":"Nat Mater"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.005_b0095","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","article-title":"Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids","volume":"107","author":"Heyes","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2022.06.005_b0100","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.vaccine.2022.06.005_b0105","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf4398","article-title":"Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2022.06.005_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.vaccine.2022.06.005_b0115","unstructured":"Moderna, 2022. Third Annual Vaccines Day. https:\/\/s29.q4cdn.com\/435878511\/files\/doc_presentations\/2022\/03\/Vaccines-Day-2022-Final-Slides-(03.pdf."},{"key":"10.1016\/j.vaccine.2022.06.005_b0120","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, et al. mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056\/NEJMoa2022483. Epub 2020 Jul 14. PMID: 32663912; PMCID: PMC7377258."},{"issue":"19","key":"10.1016\/j.vaccine.2022.06.005_b0125","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.06.005_b0130","unstructured":"Medicines and Healthcare products Regulatory Agency. Public Assessment Report for Moderna COVID-19 Vaccine. 2021 April 07. https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-moderna."},{"key":"10.1016\/j.vaccine.2022.06.005_b0135","unstructured":"Medicines and Healthcare products Regulatory Agency. Summary of Product Characteristic for COVID-19 Vaccine Moderna. 2021 June 25. Available at: Summary of Product Characteristics for COVID-19 Vaccine Moderna - GOV.UK (www.gov.uk)."},{"key":"10.1016\/j.vaccine.2022.06.005_b0140","unstructured":"UpToDate. 2021 June 10. Available at: https:\/\/www.uptodate.com\/contents\/coronavirus-disease-2019-covid-19-clinical-features."},{"key":"10.1016\/j.vaccine.2022.06.005_b0145","unstructured":"Oliver S. ACIP Meeting: Data and clinical considerations for additional doses in immunocompromised people; 2021 July 22. Available at: ACIP Data and Clinical Considerations for Additional Doses in Immunocompromised People (cdc.gov)."},{"key":"10.1016\/j.vaccine.2022.06.005_b0150","unstructured":"Centers for Disease Control and Prevention. COVID-19 in Children and Teens; 2021 March 17. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/daily-life-coping\/children\/symptoms.html."},{"key":"10.1016\/j.vaccine.2022.06.005_b0155","unstructured":"Centers for Disease Control and Prevention. MIS and COVID-19; 2021 June 25. Available at: https:\/\/www.cdc.gov\/mis-c\/index.html."},{"key":"10.1016\/j.vaccine.2022.06.005_b0160","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.15585\/mmwr.mm6938e1","volume":"69","author":"Delahoy","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.06.005_b0165","unstructured":"Centers for Disease Control and Prevention. Older Adults; 2021 July 3. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/older-adults.html."},{"key":"10.1016\/j.vaccine.2022.06.005_b0170","unstructured":"McClung N. ACIP Meeting: Epidemiology of Individuals at Increased Risk of COVID-19 Disease; 2020 Aug 26. Available at: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2020-08\/COVID-05-McLung.pdf."},{"issue":"24","key":"10.1016\/j.vaccine.2022.06.005_b0175","doi-asserted-by":"crossref","first-page":"759","DOI":"10.15585\/mmwr.mm6924e2","article-title":"Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020","volume":"69","author":"Stokes","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.005_b0180","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/infdis\/jiaa077","article-title":"A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period","volume":"221","author":"Yu","year":"2020","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.06.005_b0185","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.005_b0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20568-4","article-title":"Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)","volume":"12","author":"van Kampen","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2022.06.005_b0195","unstructured":"Centers for Disease Control and Prevention. COVID-19 Pandemic Planning Scenarios; 2021 March 19. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/planning-scenarios.html."},{"key":"10.1016\/j.vaccine.2022.06.005_b0200","unstructured":"World Health Organization. Scientific Briefing: Estimating mortality from COVID-19; 2020 Aug 4. Available at: https:\/\/www.who.int\/news-room\/commentaries\/detail\/estimating-mortality-from-covid-19."},{"key":"10.1016\/j.vaccine.2022.06.005_b0205","unstructured":"Griffith DM et al. Prev Chronic Dis 2020;17:200247, doi: 10.5888\/pcd17.200247.CDC. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/investigations-discovery\/hospitalization-death-by-race-ethnicity.html"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.005_b0210","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7326\/M20-3689","article-title":"Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study","volume":"173","author":"del Amo","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.005_b0215","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3018(20)30305-2","article-title":"HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform","volume":"8","author":"Bhaskaran","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2022.06.005_b0220","doi-asserted-by":"crossref","unstructured":"Tesoriero JM, Swain CE, Pierce JL, et al. Elevated COVID-19 outcomes among persons living with diagnosed HIV infection in New York State: Results from a population-level match of HIV, COVID-19, and hospitalization databases. Preprint. medRxiv. 2020;2020.11.04.20226118. Published 2020 Nov 6. doi:10.1101\/2020.11.04.20226118.","DOI":"10.1101\/2020.11.04.20226118"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.005_b0225","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.06.005_b0230","doi-asserted-by":"crossref","unstructured":"Yilmaz A, Marklund E, Andersson M, et al. Upper Respiratory Tract Levels of Severe Acute Respiratory Syndrome Coronavirus 2 RNA and Duration of Viral RNA Shedding Do Not Differ Between Patients With Mild and Severe\/Critical Coronavirus Disease 2019. J Infect Dis. 2021;223(1):15-18. doi:10.1093\/infdis\/jiaa632.","DOI":"10.1093\/infdis\/jiaa632"},{"key":"10.1016\/j.vaccine.2022.06.005_b0235","doi-asserted-by":"crossref","unstructured":"Hogan CA, Stevens BA, Sahoo MK, Huang C, Garamani N, Gombar S, Yamamoto F, Murugesan K, Kurzer J, Zehnder J, Pinsky BA. High Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease. Clin Infect Dis. 2021 May 4;72(9):e291-e295. doi: 10.1093\/cid\/ciaa1054. PMID: 32965474; PMCID: PMC7543277.","DOI":"10.1093\/cid\/ciaa1054"},{"issue":"6483","key":"10.1016\/j.vaccine.2022.06.005_b0240","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"35","key":"10.1016\/j.vaccine.2022.06.005_b0245","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2022.06.005_b0250","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J Control Release"},{"issue":"15","key":"10.1016\/j.vaccine.2022.06.005_b0255","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMc2102179","article-title":"Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine","volume":"384","author":"Wu","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2022.06.005_b0260","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01313-21","article-title":"Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants","volume":"95","author":"Choi","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.06.005_b0265","unstructured":"Vaccine and Related Biological Products Advisory Committee: Meeting Briefing Document. 2020 December 17. Available at: Vaccines and Related Biological Products Advisory Committee. December 17, 2020. Meeting Briefing Document - FDA."},{"key":"10.1016\/j.vaccine.2022.06.005_b0270","unstructured":"Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States; 2021 July 16. Available at: Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC."},{"issue":"7830","key":"10.1016\/j.vaccine.2022.06.005_b0275","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.vaccine.2022.06.005_b0280","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2022.06.005_b0285","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.immuni.2021.06.018","article-title":"COVID-19 vaccine mRNA-1273elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge","volume":"54","author":"DiPiazza","year":"2021","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.005_b0290","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.005_b0295","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2022.06.005_b0300","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.vaccine.2022.06.005_b0305","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2022.06.005_b0310","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","volume":"39","author":"Chu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.005_b0315","doi-asserted-by":"crossref","unstructured":"Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. Preprint. bioRxiv. 2021;2021.01.25.427948. Published 2021 Jan 25. doi:10.1101\/2021.01.25.427948.","DOI":"10.1101\/2021.01.25.427948"},{"issue":"9","key":"10.1016\/j.vaccine.2022.06.005_b0320","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.7326\/L21-0282","article-title":"Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series [published online ahead of print, 2021 Jun 15]","volume":"174","author":"Werbel","year":"2021","journal-title":"Ann Intern Med"},{"issue":"36","key":"10.1016\/j.vaccine.2022.06.005_b0325","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.vaccine.2022.06.005_b0330","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices \u2014 United States, June 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.06.005_b0335","doi-asserted-by":"crossref","unstructured":"Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine \u2013 United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 125-129. DOI: http:\/\/ dx.doi.org\/10.15585\/mmwr.mm7004e1.","DOI":"10.15585\/mmwr.mm7004e1"},{"key":"10.1016\/j.vaccine.2022.06.005_b0340","unstructured":"Shimabukuro T. COVID-19 Vaccine Safety Updates: Advisory Committee on Immunization Practices (ACIP); June 23, 2021. Available at: COVID-19 Vaccine safety updates (cdc.gov)."},{"key":"10.1016\/j.vaccine.2022.06.005_b0345","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.toxrep.2021.04.003","article-title":"Safety of COVID-19 vaccines administered in the EU: Should we be concerned?","volume":"8","author":"Hern\u00e1ndez","year":"2021","journal-title":"Toxicol Rep"},{"issue":"24","key":"10.1016\/j.vaccine.2022.06.005_b0350","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2104983","article-title":"Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons","volume":"384","author":"Shimabukuro","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.06.005_b0355","unstructured":"ModernaInc. Fact Sheet for Recipients And Caregivers: Emergency Use Authorization (EUA) Of The Moderna Covid-19 Vaccine to Prevent Coronavirus Disease 2019 (Covid-19) in Individuals 18 Years of Age and Older; 2022 Jan 31. Available at: Moderna COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers (fda.gov)."},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.005_b0360","doi-asserted-by":"crossref","first-page":"e2037069","DOI":"10.1001\/jamanetworkopen.2020.37069","article-title":"COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State","volume":"4","author":"Tesoriero","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.005_b0365","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1016\/S2352-3018(20)30111-9","article-title":"COVID-19 in patients with HIV: clinical case series","volume":"7","author":"Blanco","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2022.06.005_b0370","doi-asserted-by":"crossref","unstructured":"Gervasoni C, Meraviglia P, Riva A, et al. Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. Clin Infect Dis. 2020;71(16):2276-2278. doi:10.1093\/cid\/ciaa579.","DOI":"10.1093\/cid\/ciaa579"},{"key":"10.1016\/j.vaccine.2022.06.005_b0375","doi-asserted-by":"crossref","unstructured":"Sigel K, Swartz T, Golden E, et al. Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. Clin Infect Dis. 2020;71(11):2933-2938. doi:10.1093\/cid\/ciaa880.","DOI":"10.1093\/cid\/ciaa880"},{"issue":"12","key":"10.1016\/j.vaccine.2022.06.005_b0380","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/QAD.0000000000002643","article-title":"Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study","volume":"34","author":"Inciarte","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2022.06.005_b0385","unstructured":"European Medicines Agency. Assessment Report COVID-19 Vaccine Moderna. Committee for Medicinal Products for Human Use. 11 March 2021. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.vaccine.2022.06.005_b0390","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"issue":"12","key":"10.1016\/j.vaccine.2022.06.005_b0395","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.5858\/arpa.2020-0471-SA","article-title":"Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers","volume":"144","author":"Tjendra","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.vaccine.2022.06.005_b0400","unstructured":"ModernaTX, Inc. (April 16, 2021-). A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls. Identifier NCT04860297. Available at: A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants - Full Text View - ClinicalTrials.gov."},{"key":"10.1016\/j.vaccine.2022.06.005_b0405","unstructured":"Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with High Risk for Severe COVID-19: Information for Healthcare Providers; 2021 May 13. Available at: (https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html)."},{"key":"10.1016\/j.vaccine.2022.06.005_b0410","unstructured":"Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents [published online ahead of print, 2021 Aug 11]. N Engl J Med. 2021;10.1056\/NEJMoa2109522. doi:10.1056\/NEJMoa2109522 Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/34379915\/."},{"issue":"17","key":"10.1016\/j.vaccine.2022.06.005_b0415","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.2020.19124","article-title":"Association of SARS-CoV-2 Test Status and Pregnancy Outcomes","volume":"324","author":"Ahlberg","year":"2020","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.vaccine.2022.06.005_b0420","doi-asserted-by":"crossref","first-page":"759","DOI":"10.15585\/mmwr.mm6924e2","article-title":"Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30 2020","volume":"69","author":"Stokes","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.005_b0425","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.005_b0430","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and Heterologous Covid-19 Booster Vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.005_b0435","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41591-022-01739-w","article-title":"Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial","volume":"28","author":"Chu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.06.005_b0440","article-title":"Myocarditis Analyses in the Vaaccine Safety Datalink: Rapid Cycle Analayses and \u201cHead-to-Head\u201d Product Comparisons","author":"Klein","year":"2022","journal-title":"Kaiser Permamente Vaccine Study Center"},{"key":"10.1016\/j.vaccine.2022.06.005_b0445","unstructured":"SPIKEVAX\u00ae. Package Insert. https:\/\/www.fda.gov\/media\/155675\/download."},{"issue":"34","key":"10.1016\/j.vaccine.2022.06.005_b0450","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1016\/j.vaccine.2020.06.017","article-title":"The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines","volume":"38","author":"Kim","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.005_b0455","unstructured":"World Health Organization. Weekly Epidemiological Record. No. 28, 2019, 94, 310-312."},{"key":"10.1016\/j.vaccine.2022.06.005_b0460","unstructured":"World Health Organization. Weekly Epidemiological Record. No. 4, 2020, 95, 29-30."},{"key":"10.1016\/j.vaccine.2022.06.005_b0465","doi-asserted-by":"crossref","unstructured":"Doria-Rose N, et al. mRNA-1273 Study Group. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 Jun 10;384(23):2259-2261. doi: 10.1056\/NEJMc2103916. Epub 2021 Apr 6. Erratum in: N Engl J Med. 2022 Feb 3;386(5):500. PMID: 33822494; PMCID: PMC8524784.","DOI":"10.1056\/NEJMx220001"},{"key":"10.1016\/j.vaccine.2022.06.005_b0470","doi-asserted-by":"crossref","unstructured":"Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices \u2014 United States, June 2021. MMWR Morb Mortal Wkly Rep 2021;70:977\u2013982. DOI: http:\/\/dx.doi.org\/10.15585\/mmwr.mm7027e2external icon.","DOI":"10.15585\/mmwr.mm7027e2"},{"issue":"6576","key":"10.1016\/j.vaccine.2022.06.005_b0475","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.06.005_b0480","unstructured":"Israeli Ministry of Health. Surveillance of Myocarditis (Inflammation of the Heart Muscle) Cases Between December 2020 and May 2021 (Including). Available at: https:\/\/www.gov.il\/en\/departments\/news\/01062021-03. Accessed May 2, 2022."},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.005_b0485","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jamacardio.2021.2833","article-title":"Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military","volume":"6","author":"Montgomery","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"14","key":"10.1016\/j.vaccine.2022.06.005_b0490","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events After COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.06.005_b0495","unstructured":"Centers for Disease Control and Prevention. COVID-19 VaST Work Group Report \u2013 May 17, 2021. Available at: https:\/\/www.cdc.gov\/vaccines\/acip\/work-groups-vast\/report-2021-05-17.html. Accessed April 29, 2022."},{"issue":"27","key":"10.1016\/j.vaccine.2022.06.005_b0500","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices - United States, June 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.06.005_b0505","doi-asserted-by":"crossref","unstructured":"Tetjel et al, Myocarditis and pericarditis: Case definition and guidelines for collection,analysis and presentation of immunization safety data. Vaccine, 40: p 1499-1511, 2022.","DOI":"10.1016\/j.vaccine.2021.11.074"},{"key":"10.1016\/j.vaccine.2022.06.005_b0510","unstructured":"Kracalik, I. Myocarditis Outcomes Following mRNA COVID-19 Vaccination. Advisory Committee on Immunization Practices. 2022. Available at: https:\/\/stacks.cdc.gov\/view\/cdc\/114157. Accessed May 17, 2022."},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.005_b0515","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: current evidence and future directions","volume":"18","author":"Tsch\u00f6pe","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.vaccine.2022.06.005_b0520","unstructured":"Centers for Disease Control and Prevention. Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. 2022. Available at: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/managing-anaphylaxis.html. Accessed May 15, 2022."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:15:57Z","timestamp":1759403757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22007526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":104,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22007526"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Brighton Collaboration standardized template with key considerations for a benefit\/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}